SEC FORM 4

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

BIENAIME JEAN JACQUES

(Last)

(First)

(Middle)

C/O BIOMARIN PHARMACEUTICAL INC.

770 LINDARO ST.

(Street)

SAN RAFAEL

94901

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
BIOMARIN PHARMACEUTICAL INC [ BMRN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
05/05/2016

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/05/2016⁽¹⁾	05/05/2016	M		10,000	A	$12.99	10,000	I	Shares held in irrevocable trust for Guillaume Bienaime⁽²⁾
Common Stock	05/05/2016⁽¹⁾	05/05/2016	S		10,000	D	$80.1489⁽³⁾	0	I	Shares held in irrevocable trust for Guillaume Bienaime⁽²⁾
Common Stock	05/05/2016⁽¹⁾	05/05/2016	M		10,000	A	$12.99	10,000	I	Shares held in irrevocable trust for Pierre Bienaime⁽²⁾
Common Stock	05/05/2016⁽¹⁾	05/05/2016	S		10,000	D	$80.1489⁽³⁾	0	I	Shares held in irrevocable trust for Pierre Bienaime⁽²⁾
Common Stock	05/05/2016⁽¹⁾	05/05/2016	M		10,000	A	$12.99	10,000	I	Shares held in irrevocable trust for Paul Bienaime⁽²⁾
Common Stock	05/05/2016⁽¹⁾	05/05/2016	M		10,000	D	$80.1489⁽³⁾	0	I	Shares held in irrevocable trust for Paul Bienaime⁽²⁾
Common Stock	05/05/2016⁽¹⁾	05/05/2016	M		10,000	A	$12.99	10,000	I	Shares held in irrevocable trust for Marc Bienaime⁽²⁾
Common Stock	05/05/2016⁽¹⁾	05/05/2016	S		10,000	D	$80.1489⁽³⁾	0	I	Shares held in irrevocable trust for Marc Bienaime⁽²⁾
Common Stock	05/05/2016⁽¹⁾	05/05/2016	M		20,000	A	$12.99	20,000	I	Shares held in irrevocable trust for Aurelie Mitsuki Bienaime & Anais Kimiko Bienaime⁽²⁾
Common Stock	05/05/2016⁽¹⁾	05/05/2016	S		20,000	D	$80.1489⁽³⁾	0	I	Shares held in irrevocable trust for Aurelie Mitsuki Bienaime & Anais Kimiko Bienaime⁽²⁾
Common Stock	05/06/2016	05/06/2016	F		5,479	D	$80.8	390,156	D
Common Stock								25,758	I	Shares held by Bienaime Family Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy) Common Stock	$12.99	05/05/2016⁽¹⁾	05/05/2016	M			10,000	11/11/2006	05/10/2016	Common Stock	10,000	$0	0⁽⁴⁾	I	Held in irrevocable trust for Guillaume Bienaime⁽²⁾
Stock Option (right to buy) Common Stock	$12.99	05/05/2016⁽¹⁾	05/05/2016	M			10,000	11/11/2006	05/10/2016	Common Stock	10,000	$0	0⁽⁴⁾	I	Held in irrevocable trust for Pierre Bienaime⁽²⁾
Stock Option (right to buy) Common Stock	$12.99	05/05/2016⁽¹⁾	05/05/2016	M			10,000	11/11/2006	05/10/2016	Common Stock	10,000	$0	0⁽⁴⁾	I	Held in irrevocable trust for Paul Bienaime⁽²⁾
Stock Option (right to buy) Common Stock	$12.99	05/05/2016⁽¹⁾	05/05/2016	M			10,000	11/11/2006	05/10/2016	Common Stock	10,000	$0	20,000⁽⁴⁾	I	Held in irrevocable trust for Marc Bienaime⁽²⁾
Stock Option (right to buy) Common Stock	$12.99	05/05/2016⁽¹⁾	05/05/2016	M			20,000	11/11/2006	05/10/2016	Common Stock	20,000	$0	0⁽⁴⁾	I	Held in irrevocable trust for Aurelie Mitsuki Bienaime & Anais Kimiko Bienaime⁽²⁾

Explanation of Responses:

1. Transaction made pursuant to a Rule 10b5-1 trading plan executed on August 17, 2015.

2. The reporting person's spouse is the trustee of each child's trust.

3. The price in column 4 is a weighted average price. The price actually received ranged from $79.46 to $82.50. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

4. Reflects the numbers of stock options outstanding after the transaction from this specific stock option grant.

	/s/ Laura Randall Woodhead, Attorney-in-Fact	05/09/2016
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.